Shandong Realcan Pharmaceutical Co Ltd (002589)

Currency in CNY
3.10
0.00(0.00%)
Closed·

002589 Financial Summary

Key Ratios

P/E Ratio237.25
Price/Book0.85
Debt / Equity120.4%
Return on Equity0.74%
Dividend Yield0.35%
EBITDA192.34M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2022
01/01
2023
01/01
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.01%
Dividend Yield
0.35%
Industry Median 1.51%
Annualised payout
0.01
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
Apr 29, 2025
EPS / Forecast
0.01 / --
Revenue / Forecast
1.76B / --
EPS Revisions
Last 90 days

FAQ

What were Realcan Pharm A's earnings for the latest quarter?

The Realcan Pharm A EPS (TTM) is 0.01. Realcan Pharm A reported sales of 1,756.65, net income of 14.17, and EPS of 0.01 for the latest quarter.

What was Realcan Pharm A's net income for the latest quarter?

Realcan Pharm A's net income for the latest quarter was 14.17.

How did Realcan Pharm A's performance compare year-over-year in the latest quarter?

The company's revenue moved from 1,910.15 in the previous quarter to 1,756.65 in the latest quarter, and net income moved from -18.18 to 14.17 compared to the previous quarter.

What is Realcan Pharm A's net profit margin on a TTM basis?

Realcan Pharm A's trailing twelve months (TTM) net profit margin is 0.26%.

How does Realcan Pharm A's debt to equity ratio compare to industry standards?

Realcan Pharm A's total debt-to-equity ratio is 120.40%.

What is Realcan Pharm A's return on investment on a TTM basis?

Realcan Pharm A's trailing twelve months (TTM) return on investment (ROI) is 0.74%.

Did Realcan Pharm A gain or lose cash last quarter?

In the latest quarter, Realcan Pharm A's net change in cash was 283.32 million.

What were Realcan Pharm A's total assets and liabilities in the latest quarter?

As of the latest quarter, Realcan Pharm A reported total assets of 16,040.34 million and total liabilities of 9,938.78 million.

How has Realcan Pharm A's total revenue grown this year?

Realcan Pharm A's total revenue was 1,910.15 in the previous quarter and 1,756.65 in the latest quarter.

What is Realcan Pharm A's gross margin on a TTM basis?

Realcan Pharm A's trailing twelve months (TTM) gross margin is 11.30%.

What was Realcan Pharm A's revenue per share for the latest quarter?

Realcan Pharm A's revenue per share for the latest quarter was 6.97.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.